Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.50 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | USP7 | Q93009 | 2/20 | 0.43 |
| ▸ | USP10 | Q14694 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437803 | 0.93 | UTS2R (0.46) | UTS2RTP53SMN1; SMN2MAPTFAAH | |
| SCHEMBL12437727 | 0.89 | UTS2R (0.45) | UTS2RTP53SMN1; SMN2MAPTFAAH | |
| SCHEMBL12437722 | 0.87 | UTS2R (0.45) | UTS2RTP53SMN1; SMN2MAPTFAAH | |
| SCHEMBL12437770 | 0.87 | UTS2R (0.46) | TMEM97SIGMAR1UTS2RTP53SMN1; SMN2 | |
| SCHEMBL12437755 | 0.87 | UTS2R (0.47) | TMEM97SIGMAR1UTS2RTP53SMN1; SMN2 | |
| SCHEMBL12437723 | 0.86 | MAPT (0.51) | UTS2RTP53CACNA1GMAPTKDM4E | |
| SCHEMBL12437702 | 0.86 | MEN1 (0.47) | UTS2RTP53MAPTFAAHMEN1 | |
| SCHEMBL12437720 | 0.86 | UTS2R (0.46) | UTS2RTP53SMN1; SMN2MAPTFAAH | |
| SCHEMBL12437747 | 0.86 | UTS2R (0.60) | UTS2RTP53SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL12437709 | 0.86 | UTS2R (0.51) | UTS2RTP53MAPTFAAHGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| WO-2007098086-A2 | HYDROXYPIPERIDINE DERIVATIVES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | TMEM97 1986/4885SIGMAR1 1733/4885UTS2R 854/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | TMEM97 1986/4885SIGMAR1 1733/4885UTS2R 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.